Dr. Kennedy is survived by his wife, the former Kathryn Davis, a biostatistician who contributed to his reviews of coronary therapies.
Coronary reperfusion therapy, discharge statin therapy, and aspirin were protective factors, while discharge diuretic therapy increased long-term stroke risk.
The coronary gene therapy research, led by Dr. Jeffrey M. Isner of St. Elizabeth's Hospital in Brighton, Mass., and Tufts University, is reported in today's issue of Circulation, a journal published by the American Heart Association.
Previous studies have reported that coronary reperfusion therapy with percutaneous coronary intervention improves outcomes in out-of-hospital cardiac arrest (OHCA) patients [ 5- 8].
Two clinical studies showed that myocardial infarct size after coronary reperfusion therapy was larger by 30 80 % in diabetic patients than in non-diabetic patients [ 27, 28].
The current study was undertaken to examine the effects of coronary revascularisation therapy in patients who had stabilised after an ACS.
To examine the effects of coronary revascularisation therapy in patients who have stabilised after an acute coronary syndrome (ACS), we used a propensity score analysis 6 7 based on the likelihood of undergoing revascularisation after stabilisation.
Previous studies lumped together patients with such markedly different clinical characteristics. 2 5–7 As a result, they were unable to evaluate whether patients who met stabilisation criteria also derived substantial benefit from coronary revascularisation therapy.
Iwasaki and Matsumoto [ 36] studied the incidence of myocardial perfusion defect by 64-MDCT at rest in patients with significant stenosis and the effect of coronary revascularization therapy on myocardial perfusion.
Underuse of coronary reperfusion therapy among patients with comorbid diseases may account for some of the increased mortality associated with comorbidity within the first 30 days after hospitalisation for myocardial infarction.
